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To investigate mutations in genes that are potential modifiers of spinal muscular atrophy
(SMA) severity.
Methods
We performed a hypothesis-based search into the presence of variants in fused in sarcoma
(FUS), transactive response DNA-binding protein 43 (TDP-43), plastin 3 (PLS3), and profilin
2 (PFN2) in a cohort of 153 patients with SMA types 1–4, including 19 families. Variants were
detected with targeted next-generation sequencing and confirmed with Sanger sequencing.
Functional effects of the identified variants were analyzed in silico and for PLS3, by analyzing
expression levels in peripheral blood.
Results
We identified 2 exonic variants in FUS exons 5 and 6 (p.R216C and p.S135N) in 2 unrelated
patients, but clinical effects were not evident. We identified 8 intronic variants in PLS3 in 33
patients. Five PLS3 variants (c.1511+82T>C; c.748+130 G>A; c.367+182C>T; c.891-25T>C
(rs145269469); c.1355+17A>G (rs150802596)) potentially alter exonic splice silencer or ex-
onic splice enhancer sites. The variant c.367+182C>T, but not RNA expression levels, cor-
responded with a more severe phenotype in 1 family. However, this variant or level of PLS3
expression did not consistently correspond with a milder or more severe phenotype in other
families or the overall cohort. We found 3 heterozygous, intronic variants in PFN2 and TDP-43
with no correlation with clinical phenotype or effects on splicing.
Conclusions
PLS3 and FUS sequence variants do not modify SMA severity at the population level. Specific
variants in individual patients or families do not consistently correlate with disease severity.
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Proximal hereditary spinal muscular atrophy (SMA) is caused
by homozygous deletion or mutation in the survival motor
neuron 1 (SMN1) gene, combined with the presence of
a variable number of copies of a related gene, SMN2.1 SMA
has a striking spectrum of severity, ranging from severe an-
tenatal to mild adult onset motor deficits. This variation is
reflected by the widely used classification system that dis-
tinguishes types 0/1a - 4, based on the age at onset and the
higher of 2 acquired motor milestones (e.g., sitting and
walking independently).2
The backup SMN2 gene determines residual SMN protein levels
in cells.3,9,41 The SMN protein has multiple functions, including
messenger RNA (mRNA) and ubiquitin homeostasis,4,5 axonal
transport,6,7 and endocytosis.8 Differences in SMA severity are
primarily explained by variation in copy numbers of SMN2, but
still 20%–40% of the clinical variability does not correspond with
the SMN2 copy number.9,10 SMN2 point mutations, in particular
c.859G>C,11 and possible epigenetic variation12 have been
identified as additional severity modifying factors by changing
amino acids, disrupting exonic splice enhancer (ESE) or exonic
splice silencer (ESS), or altering expression of SMN in other
ways. However, none of these intragenic SMN2modifiers explain
the full range of severity in SMA. It is therefore likely that there
are additional modifiers of disease severity outside the SMN2
gene.10,13 Candidates include genes encoding proteins that in-
teract with SMN in complexes or that have been shown to rescue
SMN-dependent downstream cellular functions. For example,
mutations in fused in sarcoma (FUS) can disrupt the axonal
distribution pattern of SMNandwere found to be associatedwith
lower motor neuron syndromes.14 Moreover, transactive re-
sponseDNA-binding protein 43 (TDP-43) is amajor constituent
of pathologic ubiquitinated protein aggregates in target tissues of
patients with sporadic (lower) motor neuron disease.15,16 In
addition, profilin 2 (PFN2) is important for preservation of cy-
toskeletal integrity and neuritogenesis.17,18 Of interest, each of
these genes has also been implicated in other types of motor
neuron disease and therefore provide possible functional links
between SMA and other motor neuron diseases.15,16,19–21
The plastin 3 (PLS3) gene has been mapped to chromosome
Xq23 and encodes an actin-binding protein.13 Although PLS3
probably does not directly interact with SMN, it represents an
additional SMA severity modifying candidate gene because its
overexpression was found in asymptomatic women with
a homozygous SMN1 deletion who had male relatives with
SMA type 3.13 Although the genetic background of PLS3
overexpression in individuals is unclear, PLS3 overexpression
in experimental models for SMN deficiency reversed defects
in axonogenesis and endocytosis.8,13,22
The incidence and effect of variation in these potential mod-
ifying genes in patients with SMA have not yet been explored
in detail. Identification of these modifiers will help to dissect
cellular processes and pathways that are affected by SMN de-
ficiency and that may represent further therapeutic targets for
SMA. We therefore investigated the presence of single nucle-
otide variants in PLS3, FUS, TDP-43, and PFN2 in a cohort of
153 patients with SMA types 1–4 to explore their potential role
as SMA severity modifying genes. We included 19 families, 11
of which had sibs with differing degrees of severity.
Methods
We enrolled patients with SMA types 1–4 between Septem-
ber 2010 and August 2014. Methods are described in ap-
pendix e-1 (links.lww.com/NXG/A203).
Standard protocol approvals, registrations,
and patient consents
The Medical Ethical Committee of the University Medical
Center Utrecht approved the study protocol. This study was
registered at the Dutch registry for clinical studies and trials
(ccmo-online.nl).
Data availability
Anonymized data that support the findings of this study




We included 153 patients. Characteristics of the participants
are summarized in table 1.
All but 1 patient had homozygous deletion of at least exon 7 of
SMN1. One patient had a heterozygous deletion of SMN1 and
a point mutation in exon 4 (c.542A>G), which created a new
splice-donor site within exon 4 of SMN1 and an out-of-frame
transcript (i.e., null allele).
Forty-two patients had a discordant phenotype (16 SMA type
1 with 3 or 4 SMN2 copies; 8 SMA type 2 with 2 or 4 SMN2
copies; 21 SMA type 3 with 3 or 5 SMN2 copies). Two patients
with a discordant phenotype of SMA type 2 and only 2 SMN2
copies harbored the c.859G>C mutation in SMN2 exon 7.11
We included 19 families encompassing a total of 35 siblings
and first-degree relatives. Eleven (58%) families, including
Glossary
ESE = exonic splice enhancer; ESS = exonic splice silencer; FUS = fused in sarcoma; PFN2 = profilin 2; PLS3 = plastin 3;
SMA = spinal muscular atrophy; SMN = survival motor neuron; TDP-43 = transactive response DNA-binding protein 43.
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26 siblings and first-degree cousins, were discordant (e.g.,
brother with SMA type 3a and sister with SMA type 2b), despite
similar SMN2 copy numbers in 17 of the 19 families (90%).
Variation in sequences of FUS, PFN2, TDP-43,
and PLS3
We identified 2 exonic variants in FUS, 8 intronic variants in
PLS3, 2 intronic variants in PFN2, and 1 intronic variant in
TDP-43. The full list of sequence variations in FUS, PFN2,
PLS3, andTDP-43 is provided in the supplementary file (table
e-1, links.lww.com/NXG/A202).
Variation in coding sequences of FUS
We identified 2 different heterozygous missense sequence
variants in FUS in 2 unrelated patients (table 2) and no
intronic variants. One patient carried a mutation in FUS exon
6 (c.646C>T; p.R216C) that is predicted to be damaging
(PolyPhen-2 score 0.997; sensitivity 0.41; specificity 0.98).
This variant has been reported previously in patients with
familial amyotrophic lateral sclerosis (ALS) with a lower
motor neuron phenotype21,23 and patients with familial es-
sential tremor.24 This patient has SMA type 1c and has 3
SMN2 copies. Disease course did not differ from what was
Table 1 Patient characteristics
Variant analysis
SMA type
1 (n = 25) 2 (n = 68) 3 (n = 53) 4 (n = 6)
1b (n = 9) 1c (n = 16) 2a (n = 38) 2b (n = 30) 3a (n = 27) 3b (n = 26) 4 (n = 6)
Sex F:M 7:2 8:8 20:18 20:10 15:12 11:15 3:3


























SMN1 copy number, n
Homozygous deletion 9 16 38 30 26 26 6
Heterozygous deletion 0 0 0 0 1a 0 0
SMN2 copy number n (%)
2 9 (100) 0 1b (3) 1b (3) 1 (4) 0 0
3 0 15 (94) 35 (92) 25 (84) 15 (56) 3 (12) 0
4 0 1 (6) 2 (5) 4 (13) 11 (40) 20 (76) 6 (100)
5 0 0 0 0 0 3 (12) 0
RNA expression analysis
SMA type
1 (n = 1) 2 (n = 17) 3 (n = 29) 4 (n = 3)
1b (n = 0) 1c (n = 1) 2a (n = 11) 2b (n = 6) 3a (n = 14) 3b (n = 15) 4 (n = 3)
Sex F:M NA 0:1 7:4 5:1 6:8 8:7 0:3
Age at inclusion in years median
(range)












SMN1 copy number, n
Homozygous deletion NA 1 11 6 14 15 3
Heterozygous deletion NA 0 0 0 0 0 0
SMN2 copy number n (%)
3 NA 1 (100) 10 (91) 4 (66) 5 (36) 1 (7) 0
4 NA 0 1 (9) 2 (34) 9 (64) 13 (86) 3 (100)
5 NA 0 0 0 0 1 (7) 0
Abbreviations: n = number; NA = not applicable; SMA = spinal muscular atrophy; SMN= survival motor neuron.
a Female patient with a heterozygous deletion of SMN1 and a point mutation in SMN1 exon 4 (c.542A>G).
b Patients with a discordant phenotype according to SMN2 copy number harboring a point mutation in SMN2 exon 7 (c.859G>C).
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expected in SMA type 1c with 3 SMN2 copies. Age at onset was
4 months, when she lost the ability to lift her head in prone
position. She has never acquired the ability to roll over or sit
without support. At the time of inclusion, she was aged 13 years
and still without respiratory support, despite episodes of pneu-
monia. This patient had a postural tremor that was not more
pronounced than in other patients with SMA types 1c or 2.
We identified another FUS variant in exon 5 (c.404G>A;
p.S135N). This FUS variant has not been reported before and
is predicted to be benign (PolyPhen-2 score 0.004; sensitivity
0.97, specificity 0.59). At the time of inclusion, the patient was
aged 19.5 years, and disease course did not differ from what
was expected in SMA type 2a. Disease onset was at 6 months,
and she carried 3 SMN2 copies. She started with noninvasive
respiratory support at age 12 years. Her elder brother, aged
22.5 years at the time of inclusion, also carried 3 SMN2 copies
but lacked the variant in FUS. He had an SMA type 2b phe-
notype reaching an additional motor milestone, i.e., standing
with support, and did not need respiratory support at age
26 years (last follow-up).
Genetic variation in PFN2 and TDP-43
Noexonic variants could be confirmed inPFN2 orTDP-43. We
identified 3 heterozygous, intronic variants in PFN2 and TDP-
43 (table e-1, links.lww.com/NXG/A202). The A/C variant in
intron 2 of PFN2 is located in an ESS, although none of the
variants were predicted to alter splicing (HumanSpliceFinder).
Variation in intronic sequences and expression
levels of PLS3
We identified a total of 8 intronic variants in PLS3 (table e-1,
links.lww.com/NXG/A202) but no exonic or coding variants.
We found 5 variants in 26 patients, affecting ESS sites
(c.748+130G>A; c.891-25TC (rs145269469); c.1377+17-
A>G (rs150802596); c.1511+82T>C) or creating new ESE
sites (c.367+182C>T; c.1511+82T>C; c.891-25T>C
(rs145269469)) (figure 1). The c.1511+82T>C variant oc-
curred in 4 patients, 3 of whom carried a second variant
(c.1511+82T>C and c.367+182C>T). None of these sites
was predicted to have an effect on splicing (HumanSplice-
Finder), although the functional effect of each variant on
ESS/ESE would remain to be determined. Minor allele fre-
quency was between 0.006 and 0.040 in all variants (Project
MinE databrowser, gnomAD, ExAC).
To analyze potential effects of these variants on PLS3 ex-
pression levels, we performed expression analysis in blood of
patients for which RNA had been collected. Expression
analysis was performed in 50 patients and 21 healthy controls
(table 1). Healthy controls (median age 68 years [range
38–78 years]) included 6 females (29%). Expression levels of
PLS3 ranged from 1.4–26.0 copies/ng copyDNA (cDNA)
(median 10.6, mean 10.8). Expression levels did not differ
between patients and controls (p = 0.6; median level in
patients: 10.2 copies/ng cDNA [range 1.7–26.0 copies/ng
cDNA]; median level in controls: 12.2 copies/ng cDNA
[range 1.4–18.0 copies/ng cDNA]), nor between males and
females (controls p = 0.8; patients with SMA p = 0.9) (figure
2A). In patients, PLS3 expression levels correlated with age in
males (n = 24) (Spearman rho −0.44; p = 0.03), but not in
females (n = 26) (Spearman rho −0.17, p = 0.41). There was
no correlation between PLS3 levels and the SMN2 copy
number (p = 0.32).
Table 2 Characteristics of 2 nonrelated patients with exonic variants in FUS
Exon Varianta Effectb MAF
SMN2
copy





0.01 3 1c; onset at 4 mo of age. Highest acquired motor
milestones: lifting head in prone position.
1c: according to age at onset combined
with 3 SMN2 copies
5 c.404G>A;
p.S135N
Benign 0.04 3 2a; age at onset 6 mo. Sits unsupported, never able
to stand or walk with support. Start noninvasive
respiratory support at 12 y.
2; brotherwith 3 SMN2, and no FUS variant
has a 2b phenotype and no respiratory
support at age 26 y.
Abbreviations: FUS = fused in sarcoma; MAF = mean allele frequency, given in %; SMN = survival motor neuron; SMA = spinal muscular atrophy.
a Both variants were heterozygous.
b Predicted possible effect of an amino acid substitution on the structure and function of a human protein by PolyPhen-2.
c Expected phenotype based on SMN2 copy number.
Figure 1 Reads of variants in PLS3
Results showing reverse reads of Sanger sequencing genomic DNA. (A)
Heterozygous variant in intron 3 (c.367+182 C>T) in a female patient. (B) No
variant in sequence of the brother, who has a milder phenotype. (C) Control
with wild-type sequence.
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Expression levels in patients carrying the variant in intron 3
(c.367+182C>T) were higher compared with patients not
carrying the variant (figure 2B) (p = 0.04), possibly indicating
a functional effect of this variant as a novel ESE. Other variants
were not associated with expression changes. We could not
perform expression analysis in patients with the c.1511+82-
T>C variant because RNA was not available.
PLS3 genotype and expression levels in relation
to clinical phenotypes
Nineteen nonrelated patients carried 1 of the 5 identified
intronic variants in PLS3 affecting an ESE or ESS. The
presence of one of the PLS3 variants was not associated
with a milder or more severe phenotype in these patients
compared with patients without a variant (p > 0.05). Six of
27 patients with a discordant phenotype carried an intronic
mutation in PLS3, but the presence of a mutation did not
correlate with a positive or negative discordant phenotype
(all mutations p adjusted > 0.05). PLS3 expression levels
did not correlate with clinical severity, e.g., SMA type
(p = 0.15).
Combined analysis of PLS3 sequences and PLS3 expression
analysis was possible in all siblings of 3 families and 7 non-
related patients (figure 2). Expression levels of PLS3 were not
associated with milder or more severe clinical phenotypes
(p = 0.53; figure 2B.)
In 1 family, the presence of the c.367+182C>T variant
corresponded with a more severe phenotype or disease
course compared with the sibling not carrying the variant
(type 2b vs 3a), whereas in another family, the variant was
present in the sibling with a milder phenotype (type 2b vs
1c) (figure 2). In the third family carrying this variant, there
was no clear effect of the variant. The siblings had SMA type
3a in line with 4 SMN2 copies, whereas their cousin had
a more severe phenotype (type 2a), which corresponded
with his 3 SMN2 copy background. In conclusion, these
findings suggest that variability in PLS3 sequence and RNA
expression does not sufficiently explain discordant severity
in our patient cohort.
Discussion
We performed a hypothesis-based mutational analysis of the
candidate disease-modifying genes PLS3, TDP-43, PFN2, and
FUS to explore their potential contribution to variability in
severity of SMA. We found no evidence for genetic associa-
tion between variation in these candidate genes and SMA
severity, although we identified specific variants in FUS and
PLS3 that may be of interest in specific cases. Our findings
suggest that other genetic modifiers, both near the SMN locus
and elsewhere in the genome, are likely to exist that modify
SMA disease severity.
Figure 2 Expression levels of PLS3
Results showing expression levels of PLS3 and the effects of (A) sex in patients and controls and (B) different intronic variants in the PLS3 gene. Expression
levels of PLS3 are expressed in copies per nanogram cDNA. TBP andHRPT1 were both used as references. Variant status of the included controls is unknown.
(A) Sex did not consistently affect expression levels in patients or controls (p = 0.5). Expression levels of PLS3 did not differ between patients and controls (p =
0.6) or SMA types (p = 0.4). (B) Patients are reflected by diamond (male) or bullet (female) with color representing SMA type. Variants in intron 3 (c.367+182C>T)
result in higher levels of PLS3 (p = 0.04; median expression levels of PLS3 in patients and controls 10.8 copies per nanogram cDNA (range 1.4–26.0 copies per
nanogram cDNA); median expression in intron 3 altered patients 19.1 copies per nanogram cDNA (range 12.1–23.0 copies per nanogram cDNA). Two siblings
of a family carrying the c.367+182C>T variant showed amore severe phenotype (type 2b) in the sibling carrying the variant comparedwith the sibling who did
not carry the variant (type 3a). The expression levels of PLS3 were only available from the sibling with the variant (marked by “X”). Another family carrying this
variant included 2 siblings and their cousin, all carrying the same variant, but having different SMA types (type 3a [siblings] and type 2a [cousin]). The siblings
had similar expression levels of PLS3 (marked by “*”). PLS3 expression level in the cousin was not available. cDNA= copy DNA; SMA = spinalmuscular atrophy.
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Mutations in FUS exons 5 and 6 have been reported pre-
viously in patients with lower motor neuron diseases.21,23,25,26
More specifically, the p.R216C mutation was previously de-
scribed in patients with sporadic ALS or patients with es-
sential tremor.21,24 The p.S135N variant has not been
described before, and it appears unlikely that this variant is
damaging, although the functionality of this particular region
of FUS is unknown.25,26 FUS and SMN proteins are known to
interact and are both involved in RNA processing.14 Of in-
terest, deleterious effects of FUSmutations, e.g., dysfunctional
axonal growth and branching defects, can be rescued by
overexpression of SMN.14 The p.R216C mutation may neg-
atively affect FUS expression or the interaction with SMN and
thereby further reduce the functionality of the SMN-FUS
complex.21 Partial penetrance of FUS mutations has been
shown by noncomplete disease segregation in familial ALS.25
However, because the SMN2 copy number of our patient
harboring the p.R216C mutation was in line with the clinical
phenotype, the effect of the FUS variant cannot at present be
further speculated on.
We did not find coding variants in PFN2 in our cohort of
patients. The SMN/PFN2a interaction has been confirmed
by previous in vivo studies27 showing alternating levels of
PFN2a and SMN to effect SMA phenotype in mice. Previous
studies showed that minimal changes in protein levels of ei-
ther SMN or PFN2 altered their interaction and the down-
stream RhoA/ROCK pathway and affected neuritogenesis.27
Although we did not find variants in PFN2, the fact that
heterozygous deletions of SMN1 with point mutations in
exon 5 containing the binding site for profilin28–32 results in
an SMA phenotype supports the importance of the SMN/
PFN2a interaction. Second, mutations in other profilins (like
profilin-1) contribute to the risk of ALS,19 but because of
variable penetrance of the mutations,19,20 it is as yet unclear
whether such mutations are a direct cause or a risk factor for
the development of motor neuron disease.
The modifying effect of PLS3 overexpression on SMA phe-
notype was first suggested by the finding of high PLS3 ex-
pression in lymphoblast cells from peripheral blood in a family
with asymptomatic or mildly affected females with a homozy-
gous SMN1 deletion.13,33,34 Studies in SMAmice and zebrafish
supported the role of PLS3 overexpression as shown by the
rescue of motor axon defects,22,35,36 improvement of neuro-
muscular junction alterations,8,22,35 and prolongation of
survival.8,37 Other reports showed conflicting results, which
may suggest that PLS3 only acts as a modifier in specific fam-
ilies or genetic backgrounds.10,33,34,38–40 We identified 5
intronic variants in PLS3 that alter splice sites and may thereby
modify clinical severity. Because the severity of modifying
effects of PLS3 has been linked to high expression levels, we
first studied the relation between these variants and expression,
followed by comparison of severity in patients with andwithout
PLS3 variants. One of the challenges of PLS3 expression
analysis is the low expression levels in blood, which has also
been reported by other groups.38,39 We used a sensitive droplet
digital PCR technique that requires only small amounts of
blood to overcome this issue, but we cannot exclude the pos-
sibility that even this technique lacks the sensitivity to detect
biologically relevant differences in PLS3 expression, at least in
blood. An alternative approach, for example, the use of fibro-
blasts rather than blood was not possible. PLS3 expression
levels were higher in patients with intron 3 (c.367+182C>T)
variant, but not in any of the other variants. We have analyzed
full-length PLS3 transcripts as described previously,13 although
this approach precludes the analysis of correlations between
specificmutations and alternative (unknown) isoforms of PLS3
and might therefore have resulted in the lack of correlation
between phenotype and expression levels. A further compari-
son of severity between patients with and without PLS3 var-
iants did not show a consistent correlation with disease severity,
with the notable exception of 1 family, where the intron 3
(c.367+182C>T) variation coincided with a more severe rather
than a milder disease course. This finding is clearly not in line
with the presumed protective effect of higher PLS3 expression
levels. Combined, our data suggest that specific rare variants in
PLS3 may alter expression levels, but the effect on the clinical
phenotype remains unclear.
In the current study, we chose to study a small number of
candidate genes in high detail. Because we used targeted next-
generation sequencing analysis in our initial screen for var-
iants, we may have missed individual mutational changes that
cannot be detected by the designed amplicons. Moreover,
genetic variants further up- or downstream of our candidate
genes are not included in the current study but may be re-
quired to further explain variation in e.g., PLS3 RNA ex-
pression. Common variants near modifying genes might affect
clinical severity, but were not explored in this study. Whole-
genome sequencing approaches might aid in the discovery of
other disease-modifying variants, although the identification
of predictors for individual patients or small numbers of
patients might be complicated by a lack of statistical power
that these kind of studies generally require.
The identification and registration of the present (dis)cordant
families with multiple affected siblings or first- or second-
degree relatives is essential in the identification of possible
disease severity modifiers, especially now that such families
will become increasingly rare due to the introduction of
presymptomatic treatment strategies, prenatal screening, or
even preimplantation selection. Larger studies through in-
ternational collaborative efforts in search for genetic modifiers
are needed, especially now that genetic modifiers such as
SMN2 have become potent targets for therapeutic strategies
and may help to identify those who benefit most from these
intensive therapies.
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